NYSE-listed pharma major Abbott Labs has inked a deal with Piramal Healthcare to acquire Piramal’s Healthcare Solutions business. Abbott to Become No. 1 Pharmaceutical Company in India with Acquisition of Piramal’s Healthcare Solutions Business. May 21, am. N) will pay $ billion to acquire the branded generics business of Piramal’s healthcare solutions accounted for about 55 percent of its.
|Published (Last):||24 March 2011|
|PDF File Size:||11.57 Mb|
|ePub File Size:||19.76 Mb|
|Price:||Free* [*Free Regsitration Required]|
Abbott, which is celebrating its th year in India, has more than 2, employees across all of its businesses there.
Abbott Completes Acquisition of Piramal’s Healthcare Solutions Business
All Comments Your Activity. This is no different for Chinese firms. India’s rapid pharmaceutical market growth is being driven largely pjramal branded generics.
It is increasingly a preferred choice for infrastructure and real estate developers as well.
It will, however, continue research in drug discovery through an affiliate company. For consumers, the great value in generics is getting it cheaper. Featured Today In Travel.
Globalization is not just for manufacturers. Abbott plans to fund the deal with cash on its balance sheet and said it would not change its earnings outlook for The upfront payment is scheduled to be made by September, with the annual payments starting in Several accquisition deals occurred over the past one year. Let’s work together to keep the conversation civil.
Today, branded generics account for acquisiyion percent of the global pharmaceutical market, have the majority of market share in the largest emerging markets, and are expected to outpace growth of patented and generic products. Facts, background information, dossiers.
piramsl By comparison, Cipla trades at about 4. Sat, May 22 In Germany, Abbott has approximately 2, employees working in manufacturing, research and development, logistics, sales and marketing.
Chaudhuri acknowledges those new realities, but with a patriotic tinge. We combine fresh and creative thinking with scientific and strategic depth According to Wharton faculty and industry experts, changing global business models and the resources needed to develop blockbuster drugs are propelling Indian companies to join forces with multinationals through strategic alliances or as targets for acquisitions. Also, Piramal’s barnds have presence across the emerging markets. Growth Through Overseas Expansion Globalization is not just for piramsl.
Abbott to pay $3.7 billion for unit of India’s Piramal
White, chairman and chief executive officer, Abbott. The transaction establishes Abbott as a leader in the medical device arena and provides expanded opportunities for future growt The sale will also involve the transfer of acquisotion employees of the domestic formulations business. BOis booming as governments battle rising healthcare costs.
Shares in Mumbai-based Piramal closed You have to create a whole organization, and that takes time. Analysts say the Indian firm will take time to incubate new businesses and even longer for returns to accrue. The Indian drug maker, which itself has made 15 acquisitions sinceinsists it will remain in the industry and invest in the remaining business.
Abbott buys Piramal’s Healthcare Solutions – PMLiVE
It will continue its drug discovery and research through Piramal Life Sciences Ltd. This deal will push Abbott to the number one slot in the Indian pharma landscape.
That is one reason pharmaceutical multinationals are doing deals with the relatively small number of well established Indian companies that have met international standards in manufacturing.
Piramal Healthcare also retains custom manufacturing, over-the-counter consumer products, diagnostic medical devices and services and clinical research, among other activities. Combined with existing product offerings, Abbott is uniquely positioned to meet the needs of one of the world’s fastest-growing pharmaceutical markets,” he said.
In fact, 10 days before the Piramal acquisition, Abbott announced a licensing and supply deal with Indian pharmaceutical company Zydus Cadila. White, chairman and chief executive officer, Abbott.